Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma.
作者信息
Moyo Tamara K, Richards Kristy L, Damania Blossom
机构信息
Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
出版信息
Clin Adv Hematol Oncol. 2010 May;8(5):372-4.
Abstract
摘要
相似文献
1
Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma.
Clin Adv Hematol Oncol. 2010 May;8(5):372-4.
2
Intracavitary cidofovir for human herpes virus-8-associated primary effusion lymphoma in an HIV-negative patient.
Clin Adv Hematol Oncol. 2010 May;8(5):367-74.
3
A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
Hematol J. 2001;2(3):172-9. doi: 10.1038/sj.thj.6200096.
4
Assessing the efficacy of cidofovir against herpesvirus-induced genital lesions in goats using different therapeutic regimens.
Antimicrob Agents Chemother. 2008 Nov;52(11):4064-8. doi: 10.1128/AAC.00725-08. Epub 2008 Sep 2.
5
Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir.
Arch Dermatol. 2010 Feb;146(2):124-6. doi: 10.1001/archdermatol.2009.363.
6
In Vitro and In Vivo Evaluation of Cidofovir as a Topical Ophthalmic Antiviral for Ocular Canine Herpesvirus-1 Infections in Dogs.
J Ocul Pharmacol Ther. 2015 Dec;31(10):642-9. doi: 10.1089/jop.2015.0024. Epub 2015 Sep 29.
7
Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects.
J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):741-5. doi: 10.1016/s0190-9622(98)70046-5.
8
Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir.
Leukemia. 2005 Mar;19(3):473-6. doi: 10.1038/sj.leu.2403646.
9
Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats.
Am J Vet Res. 2008 Feb;69(2):289-93. doi: 10.2460/ajvr.69.2.289.
10
Potent inhibition of genital herpesvirus infection in goats by cidofovir.
Antivir Ther. 2007;12(6):977-9.
引用本文的文献
1
Unraveling the Kaposi Sarcoma-Associated Herpesvirus (KSHV) Lifecycle: An Overview of Latency, Lytic Replication, and KSHV-Associated Diseases.
Viruses. 2025 Jan 26;17(2):177. doi: 10.3390/v17020177.
2
Treatment of Kaposi sarcoma with intralesional cidofovir in an HIV-negative man.
JAAD Case Rep. 2023 Oct 15;42:47-48. doi: 10.1016/j.jdcr.2023.09.036. eCollection 2023 Dec.
3
[Primary effusion lymphoma in a HIV-negative patient: case report and literatures review].
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):685-688. doi: 10.3760/cma.j.issn.0253-2727.2020.08.014.
4
Viral Oncology: Molecular Biology and Pathogenesis.
J Clin Med. 2017 Nov 29;6(12):111. doi: 10.3390/jcm6120111.
5
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
J Neurooncol. 2016 Feb;126(3):425-31. doi: 10.1007/s11060-015-1996-6. Epub 2015 Nov 24.
6
KSHV targeted therapy: an update on inhibitors of viral lytic replication.
Viruses. 2014 Nov 24;6(11):4731-59. doi: 10.3390/v6114731.
7
Human Immunodeficiency Virus (HIV)-Negative and Human Herpes Virus-8 (HHV-8)-Positive Primary Effusion Lymphoma: A Case Report and Review of the Literature.
Turk J Haematol. 2013 Mar;30(1):67-71. doi: 10.4274/tjh.53215. Epub 2013 Mar 5.
8
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Transl Res. 2013 Aug;162(2):77-92. doi: 10.1016/j.trsl.2013.03.004. Epub 2013 Apr 6.
本文引用的文献
1
A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy.
Ann Oncol. 2006 Dec;17(12):1849-50. doi: 10.1093/annonc/mdl139. Epub 2006 Jun 9.
2
Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus.
Int J Hematol. 2006 May;83(4):328-30. doi: 10.1532/IJH97.A30510.
3
Quantitative analysis of Kaposi sarcoma-associated herpesvirus (KSHV) in KSHV-associated diseases.
J Infect Dis. 2006 Mar 15;193(6):773-82. doi: 10.1086/500560. Epub 2006 Feb 7.
4
Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
J Clin Oncol. 2005 Jul 1;23(19):4372-80. doi: 10.1200/JCO.2005.07.084.
5
Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir.
Leukemia. 2005 Mar;19(3):473-6. doi: 10.1038/sj.leu.2403646.
6
Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review.
AIDS Patient Care STDS. 2004 Feb;18(2):67-73. doi: 10.1089/108729104322802498.
7
Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis.
J Clin Invest. 2004 Jan;113(1):124-36. doi: 10.1172/JCI17803.
8
High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy.
J Clin Oncol. 2003 Dec 1;21(23):4423-7. doi: 10.1200/JCO.2003.06.039. Epub 2003 Oct 27.
9
Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study.
J Clin Oncol. 2003 Nov 1;21(21):3948-54. doi: 10.1200/JCO.2003.06.013.
10
Kaposi's sarcoma-associated herpesvirus--the high cost of viral survival.
N Engl J Med. 2003 Sep 18;349(12):1107-9. doi: 10.1056/NEJMp038125.
Zotero 插件